Zusammenfassung
GRUNDLAGEN: Die Inzidenz des Kolonkarzinoms hat in den letzten Jahren zugenommen. Ebenso haben sich in den letzten Jahren neue diagnostische und therapeutische Methoden entwickelt. METHODIK: Übersicht zum Management des Kolonkarzinoms. ERGEBNISSE: Die chirurgische Therapie des Kolonkarzinoms bietet bei einer R0-Resektion die einzige Heilungschance. Im fortgeschrittenen Tumorstadium kann die Prognose durch eine Chemotherapie verbessert werden, die Effizienz neoadjuvanter Maßnahmen wurde bisher beim Kolonkarzinom nicht nachgewiesen. Unter dem Gesichtspunkt der intramuralen mikroskopischen Tumorwachstumsausbreitung ist bei den zirkulär wachsenden Kolonkarzinomen ein Sicherheitsabstand von 5 cm ausreichend. Das Ausmaß der Darmresektion wird durch die Resektion der versorgenden Gefäße und das hierdurch definierte Lymphabflussgebiet vorgegeben. Die Prognose des Kolonkarzinoms hängt in erster Linie vom Stadium bei der Diagnosestellung und von der Erfahrung des onkologischen Chirurgen ab. Wichtig für die Prognose sind besonders T-, N- und M-Stadium und das Grading. Die Bedeutung molekularer Marker des Tumorgewebes und des Serums werden derzeit noch diskutiert. SCHLUSSFOLGERUNGEN: Bei radikaler chirurgische Therapie kann auch beim Kolonkarzinom ein gutes onkologisches Ergebnis erzielt werden.
Summary
BACKGROUND: The incidence of colon carcinoma has increased during the last years, but novel diagnostic tools have also been developed. METHODS: Review on colon carcinoma. RESULTS: The only chance in the cure of colonic carcinoma is achieved by radical surgery (R0-resection). Prognosis of advanced carcinomas may improve with chemotherapy, although the efficiency of neoadjuvant designs has not yet been confirmed. Taking into account the intramural microscopic tumor spread, a safety margin of 5 cm seems to be sufficient for circumferentially growing tumors. The extent of colonic resection is defined by the resection of the blood vessels as well as its lymphovascular excision. Prognosis of colonic cancer depends on the tumor stage at the time of diagnosis as well as on the experience of the operating surgeon. In addition, TNM stage and tumor grading are very important factors, too, regarding prognosis. The impact of molecular markers of tumor tissue and serum are still being discussed. CONCLUSIONS: Radical surgical resection can yield good results in the treatment of colon carcinoma.
References
Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D (2001) National Cancer Institute Expert Panel, Guidelines 2000 for colon and rectal cancer surgery. J Nat Cancer Inst 93: 583
Rouffet F, Hay JM, Vacher B, Fingerhut A, Elhadad A, Flamant Y, Mathon C, Gainant A (1994) Curative resection for left colon carcinoma: Hemicolectomy vs. segmental colectomy: A Prospective Controlled Multicenter Trial. Dis Colon Rectum 37: 651–659
Giovannucci E (2002) Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31: 925–943
Cameron JL (2004) Current Surgical Therapy. 8th Edition. Elsevier, Mosby. pp 211–216
Fazio VW, Church JM, Delaney CP (2005) Current Therapy in Colon and Rectal Surgery. 2nd Edition. Elsevier, Mosby, pp 379–388
Lavery IC, Lopez-Kostner F, Pelley RJ, Fine RM (2000) Treatment of colon and rectal cancer. Surg Clin North Am 80 (2): 535–569
Cruz-Correa M, Giardiello FM (2002) Diagnosis and management of hereditary colon cancer. Gastroenterol Clin North Am 31: 537
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348: 919–932
De Gramont A, Boni C, Navarro M (2005) Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow- up of 4 years. J Clin Oncol 23: 246s (abstr 3501)
Wolmark N, Wieand HS, Kuebler JP (2005) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. J Clin Oncol 23: 246s (abstr LBA3500)
Giantonio BJ, Catalano PJ, Meropol NJ (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Hollywood, FL, ASCO Gastrointestinal Cancer Symposium, January 2005 (abstr 169a)
Wu JS, Fazio VW (2000) Colon cancer. Dis Colon Rectum 43(11): 1473–1486
Gatsoulis N, Roukounakis N, Kafetzis I, Mavrakis G (2004) Surgical management of large bowel obstruction due to colonic cancer. Tech Coloproctol 8 (Suppl 1): s82–s84
Doekhie FS, Peeters KC, Kuppen PJ, Mesker WE, Tanke HJ, Morreau H, van de Velde CJ, Tollenaar RA (2005) The feasibility and reliability of sentinel node mapping in colorectal cancer. Eur J Surg Oncol 31: 854–862
Saha S, Dan AG, Viehl CT, Zuber M, Wiese D (2005) Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls. Cancer Treat Res 127: 105–122
Barton JB, Langdale LA, Cummins JS, Stelzner M, Lynge DC, Mock CN, Nason KS, Billingsley KG (2002) The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer. Am J Surg 183: 499–503
Bond JH (2001) Colon polyps and cancer. Endoscopy 33 (1): 46–54
Juchems MS, Fleiter TR, Pauls S, Schmidt SA, Brambs HJ, Aschoff AJ (2006) CT colonography: comparison of a colon dissection display versus 3D endoluminal view for the detection of polyps. Eur Radiol 16(1): 68–72
Coco C, Verbo A, Manno A, Mattana C, Covino M, Pedretti G, Petito L, Rizzo G, Picciocchi A (2005) Impact of emergency surgery in the outcome of rectal and left colon carcinoma. World J Surg 29(11): 1458–1464
Landercasper J, Stolee RT, Steenlage E, Strutt PJ, Cogbill TH (1992) Treatment and outcome of right colon cancer adherent to adjacent organs or the abdominal wall. Arch Surg 127: 841–846
Pikarsky AJ (2001) Update on prospective randomized trials of laparascopic surgery for colorectal cancer. Surg Oncol Clin North Am 10(3): 639–653
Rickard MJ, Bokey EL (2001) Laparoscopy for colon cancer. Surg Oncol Clin North Am 10 (3): 579–597
Leung KL, Kwok SP, Lam SC, Lee JF, Yiu RY, Ng SS, Lai PB, Lau WY (2004) Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 363(9416): 1187–1192
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, De Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351
Macdonald JS, Astrow AB (2001) Adjuvant therapy of colon cancer. Semin Oncol 28 (1): 30–40
Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ (2006) Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 24: 190–205
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teleky, B., Kührer, I. Surgical management of cancer of the colon. Eur Surg 38, 124–128 (2006). https://doi.org/10.1007/s10353-006-0239-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10353-006-0239-7